Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue

Goineau, Aurore; Piot, B.; Malard, O.; Ferron, Christophe; Lisbona, A.; Cassagnau, E.; Delamazure, Anne-Sophie; Campion, Loı̈c; Bardet, É.

doi:10.1016/j.brachy.2014.09.011

Cited by 14 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most reports on LDR-ISBT involve a resin-only [ 17 ] or lead-only spacer (e.g. [ 29 , 30 ]) and this pattern is similar for HDR-ISBT (e.g. [ 31 , 32 ]).…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer

et al. 2016

View full text Add to dashboard Cite

PurposeTo point out the advantages and drawbacks of high-dose rate brachytherapy in the treatment of mobile tongue cancer and indicate the clinical importance of modular lead-lined spacers when applying this technique to patients.MethodsFirst, all basic steps to construct the modular spacer are shown. Second, we simulate and evaluate the dose rate reduction for a wide range of spacer configurations.ResultsWith increasing distance to the source absorbed doses dropped considerably. Significantly more shielding was obtained when lead was added to the spacer and this effect was most pronounced on shorter (i.e. more clinically relevant) distances to the source.ConclusionsThe modular spacer represents an important addition to the planning and treatment stages of mobile tongue cancer using HDR-ISBT.

show abstract

“…Most reports on LDR-ISBT involve a resin-only [ 17 ] or lead-only spacer (e.g. [ 29 , 30 ]) and this pattern is similar for HDR-ISBT (e.g. [ 31 , 32 ]).…”

Section: Discussionmentioning

confidence: 92%

“…[ 35 , 36 ]). This poses difficulties for treatment planning if shielding devices such as custom designed mandibular lead shields [ 29 ] or non-modular (e.g. ready made) shielded spacers are involved in the planning and treatment.…”

Section: Discussionmentioning

confidence: 99%

Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The dose of 40 Gy and 18 Gy were prescribed to patients when BT was used as monotherapy or boosted to 50 Gy EBRT, respectively [ 20 ]. In another study on primary mobile tongue cancer after partial glossectomy and BT monotherapy, Goineau et al reported five-year local control and five-year overall survival of 76% and 56% in the patients with LDR-BT, respectively [ 21 ]. Kakimoto et al indicated 71% three-year local control in T3 mobile tongue cancers with definitive HDR-BT [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, with this dose fraction, we still witnessed a grade 4 complication rate of about 5%, which is relatively lower than the other reports in this context. For instance, the reported rates are 16% soft tissue necrosis by Guinot et al , 16% grade 3/4 late complication by Hepel et al , and 22% of grade ≥ 2 necrosis by Goineau et al [ 20 , 21 , 34 ]. This difference in the frequency of complications is partly because we only reported grade 4 toxicity that required intensive intervention.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant high-dose-rate brachytherapy in the management of oral cavity cancers: 5 years of experience in Iran

Kazemian

Babaei

Lashkari

et al. 2017

jcb

View full text Add to dashboard Cite

Purpose: Brachytherapy is a cost-effective method for the management of oral cavity cancers in low to middle income countries. We aimed to evaluate the clinical outcomes of high-dose-rate interstitial brachytherapy (HDR-IBT) in patients with oral cavity cancer.Material and methods: From 2009 to 2013, 78 patients (49 combined external beam radiotherapy [EBRT] plus IBT and 29 IBT monotherapy) with oral cavity cancers had been treated in our center. Slightly more than half the patients were male, and the median age was 54 years. The treatment was planned based on the Paris system. The main outcomes were disease-free and overall survival.Results: The median follow-up duration was 36.5 months (range, 1.17-54.23). The actuarial four-year overall and disease-free survival rates were 83% and 65%, respectively. The local and locoregional control was achieved among 89.74% and 87.17% of patients, respectively. None of the factors including tumor size, node status, gender, and radiation modality (IBT alone vs. IBT + EBRT) had a significant statistical correlation to the local control rate. All the patients tolerated the planned treatment in the IBT alone group. Late complications included a case of trismus and three cases of catheter insertion site fibrosis.Conclusions: HDR-IBT as a monotherapy or in combination with EBRT is an appropriate option for the management of oral cavity squamous cell carcinomas, and supports the improvement in treatment outcomes and toxicity profiles in adjuvant settings.

show abstract

“…The selection of single or combined treatment modalities is based on various considerations that include disease control probability, tumor resectability, the patient's general condition, and the expertise of the hospital. For resectable tongue cancer, the mainstay of treatment is surgery, while brachytherapy may be considered as postoperative adjuvant or salvage treatment 18 , 19 or as a sole modality for unresectable or early small primary tumors. 20 Nevertheless, several critical issues in clinical brachytherapy still need to be addressed to increase antitumor efficacy and reduce side-effects.…”

Section: Discussionmentioning

confidence: 99%

Radionuclide Therapy of Unresectable Tumors with AvidinOX and ⁹⁰Y-biotinDOTA: Tongue Cancer Paradigm

Albertoni

Leoni

Rosi

et al. 2015

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Local treatment of unresectable tumors is challenging, particularly with radioactivity. Current practice relies on external beam irradiation or on a variety of medical devices for brachytherapy. Both approaches proved useful in controlling tumor growth, but are characterized by poor compliance of the patient, significant side-effects, high costs, and technological complexity, which hamper widespread use. The authors recently described a novel form of radionuclide therapy based on the oxidized form of avidin that, chemically reacting with tissue proteins, can secure radioactive biotin within the injected tissue, either when precomplexed or when taken from the blood stream after intravenous administration. AvidinOX-pretargeted 177Lu-biotinDOTA (177Lu-ST2210) is currently under clinical investigation for the treatment of liver oligometastases from colorectal cancer (clinicaltrials.gov/NCT02053324). In the present work, the authors show that injected AvidinOX can link tissues of various natures such as prostate, kidney, breast, or brain and can react by contact with scraped tissues such as skin or urinary bladder. AvidinOX injected into human OSC19 tongue cancer masses orthotopically transplanted in nude mice takes up intravenously administered 90Y-ST2210, which exerts significant antitumor activity, while preserving the integrity and functionality of the tongue. Present data confirm that AvidinOX-based radionuclide therapy is an innovative and promising approach for the local treatment of inoperable tumors.

show abstract

Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue

Cited by 14 publications

References 21 publications

Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer

Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer

Adjuvant high-dose-rate brachytherapy in the management of oral cavity cancers: 5 years of experience in Iran

Radionuclide Therapy of Unresectable Tumors with AvidinOX and ⁹⁰Y-biotinDOTA: Tongue Cancer Paradigm

Contact Info

Product

Resources

About

Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue

Cited by 14 publications

References 21 publications

Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer

Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer

Adjuvant high-dose-rate brachytherapy in the management of oral cavity cancers: 5 years of experience in Iran

Radionuclide Therapy of Unresectable Tumors with AvidinOX and 90Y-biotinDOTA: Tongue Cancer Paradigm

Contact Info

Product

Resources

About

Radionuclide Therapy of Unresectable Tumors with AvidinOX and ⁹⁰Y-biotinDOTA: Tongue Cancer Paradigm